Xifaxan Related Published Studies
Well-designed clinical trials related to Xifaxan (Rifaximin)
Safety and tolerability of rifaximin for the treatment of irritable bowel
syndrome without constipation: a pooled analysis of randomised, double-blind,
placebo-controlled trials. [2014]
[Role of rifaximin in the treatment of colonic diverticular disease]. [Article in Italian] [2012]
Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. [2011.10]
Rifaximin: new therapeutic indication and future directions. [2011.07]
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011.06]
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. [2011.05]
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). [2011.02]
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. [2011.02]
Rifaximin therapy for patients with irritable bowel syndrome without constipation. [2011.01.06]
Rifaximin therapy for patients with irritable bowel syndrome without
constipation. [2011]
Rifaximin for the treatment of hepatic encephalopathy. [2010.12]
A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. [2010.11]
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. [2010.10]
Rifaximin treatment in hepatic encephalopathy. [2010.03.25]
A randomized, double-blind, placebo-controlled study evaluating the efficacy and
safety of rifaximin for the prevention of travelers' diarrhea in US military
personnel deployed to Incirlik Air Base, Incirlik, Turkey. [2010]
Rifaximin treatment in hepatic encephalopathy. [2010]
A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. [2009.09]
Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. [2009.03]
Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. [2008.06.23]
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.10]
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.06.13]
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. [2006.10.17]
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. [2006.06]
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. [2006.05.01]
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. [2006.04.15]
A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. [2006.02]
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. [2006]
Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. [2005.12.01]
An open-label evaluation of rifaximin in the treatment of active Crohn's disease. [2005.08]
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. [2005.07.01]
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. [2005.06.30]
A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. [2005.05.17]
Rifaximin in patients with lactose intolerance. [2005.05]
Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. [2005]
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. [2004.11]
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. [2004.02]
Therapy of travelers' diarrhea with rifaximin on various continents. [2003.05]
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. [2003.01]
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. [2003.01]
Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. [2001.12.01]
Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. [2000.05]
Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. [2000.02]
Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. [2000]
A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. [1999.05]
Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. [1998.11]
Rifaximin and Helicobacter pylori eradication. [1997.07]
Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. [1997]
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. [1995.02]
Treatment of pyogenic skin infections with rifaximin cream. [1993.03]
Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. [1993]
Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. [1992.10]
[Chemotherapeutic prophylaxis in the preparation of the large intestine for surgical interventions: rifaximin P.O. vs. cephalosporin I.V.] [1992.03]
Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. [1991.05]
Well-designed clinical trials possibly related to Xifaxan (Rifaximin)
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic
encephalopathy. [2014]
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2011.09.07]
Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. [2011.04]
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2007.07.18]
Role of gut microflora and probiotic effects in the irritable bowel syndrome. [2006.08]
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. [2005.05]
Efficacy of mesalazine in the treatment of symptomatic diverticular disease. [2005.03]
Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. [2004.06]
Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. [2000.08]
Other research related to Xifaxan (Rifaximin)
Prolonged remission from hepatic encephalopathy with rifaximin: results of a
placebo crossover analysis. [2015]
Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic
encephalopathy: a randomized controlled trial. [2014]
Is rifaximin effective in maintaining remission in Crohn's disease? [2014]
Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in
patients with cirrhosis of liver. [2014]
A randomized, double-blind, controlled trial comparing rifaximin plus lactulose
with lactulose alone in treatment of overt hepatic encephalopathy. [2013]
A multicenter, double-blind, randomized, placebo-controlled study of rifaximin
for the treatment of bacterial vaginosis. [2013]
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a
meta-analysis. [2012]
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. [2011.12]
The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. [2011.11.01]
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. [2011.10]
A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. [2011.09]
The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. [2011.08]
Rifaximin for the treatment of acute infectious diarrhea. [2011.07]
A new use for Xifaxan. [2011.07]
Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. [2011.07]
Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. [2011.05]
Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. [2011.04]
Biologic properties and clinical uses of rifaximin. [2011.02]
[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]. [2011.02]
Rifaximin intake leads to emergence of rifampin-resistant staphylococci. [2011.01]
A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the
prevention of travelers' diarrhea in Mexico during the dry season. [2011]
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter
pylori associated gastroduodenal disease: a double-blind, randomized controlled
trial. [2011]
Editorial: rifaximin and minimal hepatic encephalopathy. [2011]
Rifaximin improves driving simulator performance in a randomized trial of
patients with minimal hepatic encephalopathy. [2011]
Rifaximin for the treatment of hepatic encephalopathy. [2010.12]
Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. [2010.10]
Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients with Minimal Hepatic Encephalopathy. [2010.09.13]
Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study. [2010.09]
Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. [2010.08]
Rifaximin diminishes neutropenia following potentially lethal whole-body radiation. [2010.07]
Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. [2010.07]
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. [2010.07]
Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. [2010.04]
Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. [2010.03.01]
Stability of extemporaneously prepared rifaximin oral suspensions. [2010.02.15]
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. [2010.01]
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum
is more effective than rifaximin alone in eradicating small intestinal bacterial
overgrowth. [2010]
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. [2010]
|